Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Mounjaro (tirzepatide) is a prescription drug that helps manage blood sugar levels in adults with type 2 diabetes. It works by imitating the effects of certain hormones called incretins.

Amy Schumer is sharing her experience taking Mounjaro — a prescription drug that's approved to treat Type 2 diabetes and also commonly prescribed for weight loss — after being vocal about the ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

Amy Schumer revealed she’s on a new weight loss medication after her last attempt on the drugs left her so nauseous she couldn’t lift her head off the pillow. “Mounjaro’s been great ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's what you need to know. Amy Schumer has praised weight loss drug ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country’s drug regulator, it said on Thursday. Global demand for Lilly’s ...

That was before I shed 40 pounds with the help of a weight-loss drug—and then, even more surprisingly, lost another 20 pounds after going off it.

Pharma giant Eli Lilly has launched Mounjaro, a popular weight-loss drug, in India. Priced at Rs 3,500 for 2.5 mg and Rs 4,375 for 5 mg, Mounjaro is available by prescription and aims to address ...

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP and GLP-1 receptors, which are natural incretin hormones.

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action ...